VALIDATED EXECUTIVE ENGAGEMENTS Number of executives repeatedly engaged by snail & email outreach* 
POOL + OUTREACH
| |||||||||||
With the Global Economy Walking the Tightrope, It's the Numbers that Help Understand this Uncertain World. |
COVID-19 IMPACT SURVEY MAY 2020Monitor Market Dynamics!Early March 2020, we reached out to senior enterprise executives who are driving strategy, business development, marketing, sales, product management, technology and operations at competitive firms worldwide. Our ongoing survey is focused on how this will this affect their business ecosystems. We invite you to participate in our survey and add to collective perspectives. Market movements are tracked for 2020, 2021 and broadly for the period of 2022 through 2025. Critical changes are monitored dynamically for the rest of this year. Updated analytics will reflect new and evolving market realities. Our first update scheduled for May 2020 and another in the Fall. Clients receive complimentary updates during 2020. If your company is a recent client for this project, we may have already reached out to your colleagues to participate in our program. If you're an active player in the space but hasn't yet subscribed to our project, we invite you to participate and share your perspectives. Please sign-up here.
Amid the COVID-19 crisis and the looming economic recession, the Biosimilars market worldwide will grow by a projected US$39.8 Billion, during the analysis period, driven by a revised compounded annual growth rate (CAGR) of 34.5%. Recombinant Non-glycosylated Proteins, one of the segments analyzed and sized in this study, is forecast to grow at over 34.1% and reach a market size of US$19.9 Billion by the end of the analysis period. An unusual period in history, the coronavirus pandemic has unleashed a series of unprecedented events affecting every industry. The Recombinant Non-glycosylated Proteins market will be reset to a new normal which going forwards in a post COVID-19 era will be continuously redefined and redesigned. Staying on top of trends and accurate analysis is paramount now more than ever to manage uncertainty, change and continuously adapt to new and evolving market conditions.
As part of the new emerging geographic scenario, the United States is forecast to readjust to a 32.6% CAGR. Within Europe, the region worst hit by the pandemic, Germany will add over US$1.1 Billion to the region's size over the next 7 to 8 years. In addition, over US$1.8 Billion worth of projected demand in the region will come from Rest of European markets. In Japan, the Recombinant Non-glycosylated Proteins segment will reach a market size of US$937.5 Million by the close of the analysis period. Blamed for the pandemic, significant political and economic challenges confront China. Amid the growing push for decoupling and economic distancing, the changing relationship between China and the rest of the world will influence competition and opportunities in the Biosimilars market. Against this backdrop and the changing geopolitical, business and consumer sentiments, the world's second largest economy will grow at 29.8% over the next couple of years and add approximately US$4.1 Billion in terms of addressable market opportunity. Continuous monitoring for emerging signs of a possible new world order post-COVID-19 crisis is a must for aspiring businesses and their astute leaders seeking to find success in the now changing Biosimilars market landscape. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies. Competitors identified in this market include, among others, Allergan Plc; Amgen Inc.; Biocon Ltd.; Biopartners GmbH; Boehringer Ingelheim International GmbH; Celltrion Inc.; Dr. Reddy`s Laboratories Ltd.; Eli Lilly and Company; Fresenius Kabi; Intas Pharmaceuticals Ltd.; Mylan NV; Pfizer Inc.; Samsung Bioepis Co. Ltd.; Sandoz International GmbH; STADA Arzneimittel AG; Teva Pharmaceutical Industries Ltd. |
SEGMENTS
» Product Type (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins, Recombinant Peptides) » Disease (Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases, Other Diseases)GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of WorldEXPERT PANEL REGISTRY
We're excited to add you to our Domain Expert Panel! Let's get you started.
*PRIVACY POLICY
YOUR PRIVACY MATTERS TO US!
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.